

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: - Bio-Gene Technology Limited
ABN: – 32 071 735 950

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alex Huong Soo Ding
Date of last notice	23 November 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Vana Belle Pty Ltd <Vana Belle Family A/C> 33,501,034 ordinary shares; 21,739,130 unlisted options The Director has an indirect interest. Cadogan Corporate Solutions Pty Ltd 500,000 ordinary shares. The director is a Director of the Company. HSBC Custody Nominees (Australia) Limited 121,047 ordinary shares. The Director has an indirect interest.
Date of change	21 July 2025
No. of securities held prior to change	Direct: Nil ordinary shares Indirect: 12,382,951 ordinary shares
Class	Ordinary shares
Number acquired	21,739,130
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$499,999.99
No. of securities held after change	Direct: Nil ordinary shares Indirect: 34,122,081 ordinary shares Indirect: 21,739,130 unlisted options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>21,739,130 ordinary shares subscribed for under the Placement announced on 5 May 2025 and approved by shareholders at EGM held on 14 July 2025. 21,739,130 unlisted options approved by shareholders at EGM held on 14 July 2025.</p>
--	---

Part 2 – Change of director's interests in contracts **N/A**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Edmond Tern
 Company Secretary
 21 July 2025

⁺ See chapter 19 for defined terms.